Document Detail


Resistant starch: a promising dietary agent for the prevention/treatment of inflammatory bowel disease and bowel cancer.
MedLine Citation:
PMID:  23385525     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: Resistant starch represents a diverse range of indigestible starch-based dietary carbohydrates. Resistant starch has been investigated in the past for its effects on bowel health (pH, epithelial thickness, and apoptosis of colorectal cancer cells); reduction in postprandial glycemia; increased insulin sensitivity; and effects on the gut microbiome. This review highlights advances as resistant starch gains clinical relevance as a potential treatment/preventive tool for diseases such as colorectal cancer (CRC) and diabetes.
RECENT FINDINGS: Recent articles have evaluated the comparative physiological effects of different types of resistant starch and investigated the effects of resistant starch on blood lipids, body weight, and defining resistant starch-induced changes to the micriobiome that may be important in health and disease. The most novel and relevant recent data describe a role for resistant starch in ameliorating inflammation; the use of resistant starch for optimal bowel health and prevention of CRC; and, further, that the systemic effects of resistant starch may be important for the treatment of other forms of cancer, such as breast cancer.
SUMMARY: This review describes advances in resistant starch research highlighting the gastrointestinal effects that are now being linked to systemic, whole body effects with clinical relevance. These effects have important implications for overall health and the prevention or amelioration of various chronic diseases.
Authors:
Janine A Higgins; Ian L Brown
Related Documents :
17393945 - Analysis of prostate cancer incidence using geographic information system and multileve...
16869975 - Early cancer detection among rural and urban californians.
10470455 - History and international developments in cancer staging.
1962775 - Diagnosing and staging of non-small cell lung cancer.
19175655 - Growth pattern in the muscular layer reflects the biological behaviour of colorectal ca...
21213205 - Management of pleural effusion in the cancer patient.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Current opinion in gastroenterology     Volume:  29     ISSN:  1531-7056     ISO Abbreviation:  Curr. Opin. Gastroenterol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-06     Completed Date:  2013-07-22     Revised Date:  2013-07-29    
Medline Journal Info:
Nlm Unique ID:  8506887     Medline TA:  Curr Opin Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  190-4     Citation Subset:  IM    
Affiliation:
Center for Human Nutrition, Anschutz Medical Campus, University of Colorado, Denver, Colorado, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Glucose / metabolism
Body Weight / drug effects
Colorectal Neoplasms / therapy*
Dietary Carbohydrates / therapeutic use*
Humans
Inflammatory Bowel Diseases / therapy*
Insulin Resistance / physiology
Intestines / microbiology
Metagenome / drug effects
Starch / therapeutic use*
Grant Support
ID/Acronym/Agency:
DK 038088/DK/NIDDK NIH HHS; DK43607/DK/NIDDK NIH HHS; P30 DK048520/DK/NIDDK NIH HHS; UL1 RR025780/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/Dietary Carbohydrates; 9005-25-8/Starch

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Potent Inhibition of HIV-1 Reverse Transcriptase and Replication by Nonpseudoknot, "UCAA-motif" RNA ...
Next Document:  Nutrition and diet in inflammatory bowel disease.